Vedanta Biosciences receives $50M for microbiome therapeutics — 5 points

Written by Megan Wood | June 06, 2016 | Print  |

Cambridge, Mass.-based Vedanta Biosciences raised $50 million in new equity investments for its therapies to modulate the human microbiome.

Here are five points:

1. The new investors include Rock Springs Capital, Invesco Asset Management, Health for Life Capital and PureTech.

2. Vedanta Biosciences will use the funding for its clinical studies in infectious and autoimmune diseases.

3. The financing will also help with developing the company's technology platform.

4. Vedanta Biosciences has already isolated human-associated bacterial strains as well as characterized how the immune system recognizes and responds to microbes.

5. The company has identified drug candidates composed of defined bacterial consortia, for infectious disease, immune tolerance, inflammation and immuno-oncology.

More articles on quality & infection control:
Former surgical tech tests HIV positive; compromises 1.5k patients: 5 key points
6 steps to create & maintain an outstanding ASC infection control program
Electronic monitoring increases hand hygiene compliance: 5 observations

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.